"lowered his rating to market perform from outperform, noting the stock has been the top performer in specialty pharma this year and is trading at a premium. He attributed that mostly to the strong launch of bowel-disease drug Uceris earlier this year, but wrote that a recent survey of gastroenterologists suggested to him that sales will not exceed current consensus."
So now lets break this down...we already know that SNTS stated that Uceris needs to be promoted more to reach more GI docs, hence the addition of 26 more sales people. So perrrrrrrhaps, he has surveyed GIs that has yet to evaluate the drug...just a thought. So, when those sales guys go beating down door to push Uceris...then what Mr. Gerberry? Or, maybe he saying that prescription refills will fall? I'm not really certain what he stating.
Regardless, Leerink is an investment bank first and they want on the train, no-if-and-or-buts about it!!!
Shire is a disappointing company overall, that's for sure Kitty.
However, in a PharaTimes (a critter favorite) article dated May 3, 2012 entitled "New Shire chief sets out strategy as sales disappoint" it was reported that -
"On a positive note, Firazyr (icatibant injection) for hereditary angioedema, had sales of $41.7 million, a leap of 12%."
What am I missing? (an oar for my raft??)
Am I mixing up types I & II?